Moxifloxacin Krka

Moxifloxacin, the active ingredient in Moxifloxacin Krka, is a fluoroquinolone antibiotic presented as an oral dosage form for oral use. It treats a range of bacterial infections, including community‑acquired pneumonia, acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, and skin and skin‑structure infections in adults. These agents are indicated for use in appropriate clinical settings under medical supervision.

GNH USA supplies Moxifloxacin Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance, regulatory compliance, and reliable global distribution.

Moxifloxacin is a fluoroquinolone antibiotic used to treat bacterial infections of the respiratory and skin pathways. - Community‑acquired pneumonia: Eradicates susceptible respiratory pathogens and improves clinical recovery. - Acute bacterial sinusitis: Reduces sinus inflammation by eliminating causative bacteria. - Acute bacterial exacerbation of chronic bronchitis: Controls bacterial overgrowth to prevent further lung damage. - Skin and skin‑structure infections: Clears susceptible skin pathogens and promotes wound healing.

Moxifloxacin may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nausea: Mild to moderate stomach upset. - Diarrhea: Loose stools, often self‑limiting. - Headache: Transient cranial discomfort. - Dizziness: Light‑headed sensation, especially on standing. - Rash: Minor skin irritation or erythema.

Serious or Rare Side Effects: - Tendon rupture: Sudden pain and loss of function, requiring immediate medical attention. - QT interval prolongation: May lead to cardiac arrhythmias. - Severe hypersensitivity: Anaphylaxis or angioedema. - Clostridioides difficile colitis: Persistent diarrhea with abdominal pain. - Hepatotoxicity: Elevated liver enzymes or jaundice.

Before prescribing Moxifloxacin, clinicians should consider patient‑specific factors and potential risks. - Assess cardiac history: Avoid in patients with known QT prolongation or arrhythmias. - Evaluate tendon health: Use caution in individuals with recent tendon injury or steroid use. - Monitor renal function: Dose adjustment may be needed in severe impairment. - Review concomitant medications: Check for drugs that also prolong QT or affect CYP enzymes. - Store at ambient temperature: Keep below 25 °C, in the original packaging, protected from moisture and direct sunlight.

Moxifloxacin can interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Antacids containing aluminum or magnesium: Reduce absorption; separate dosing by at least 2 hours. - Strong CYP1A2 inhibitors (e.g., fluvoxamine): May increase plasma levels, raising toxicity risk. - Drugs that prolong QT interval (e.g., quinidine, amiodarone): Heightened risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - Warfarin: May enhance anticoagulant effect; monitor INR. - Theophylline: Potential increase in serum concentrations; watch for toxicity. - Corticosteroids: May raise risk of tendon rupture; advise caution.